Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

Oktober 4, 2021
PERSBERICHT Gereglementeerde informatie – VOORWETENSCHAP 4 oktober 2021, 07:00 CET   Voltooiing van patiëntenrekrutering wordt verwacht vóór het einde van het jaar Uitlezing van het primaire eindpunt gepland in Q4 2022 59 patiënten reeds opgenomen in de Pivotal Cohort Gent, België – 4 oktober 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, de “Vennootschap”), een...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN